MBRX — Moleculin Biotech Share News
0.000.00%
Last trade - 00:00Brief: Moleculin Biotech Receives NASDAQ Letter On Regaining Compliance With Bid Price Rule 5550(A)(2)
Brief: Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
Moleculin Biotech Inc reports results for the quarter ended in December - Earnings Summary
Brief: Moleculin Reports Full Year 2023 Financial Results
Brief: Moleculin Biotech Announced 1-For-15 Reverse Stock Split
Moleculin Biotech Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data And 2024 Expectations For Multiple Data Readouts And Transition To Pivotal Phase 2B/3
Brief: Moleculin Announces Pricing Of $4.5 Million Registered Direct Offering And Concurrent Private Placement Priced At-The-Market
Brief: Moleculin Announces Positive Interim Data In Annamycin Clinical Trials
Moleculin rises on positive trial data for a type of cancer treatment
Brief: Moleculin Presents Positive Preliminary Efficacy Findings from Phase 1B/2 Clinical Trial for the Treatment of Soft Tissue Sarcomas Lung Metastases
Moleculin Biotech rises on completing enrollment for cancer drug study
Brief: Moleculin Announces New Positive Independent Report Of No Cardiotoxicity In Annamycin
Moleculin Biotech Inc reports results for the quarter ended in June - Earnings Summary
Brief: Moleculin Provides Update On Ongoing Clinical Trials And Outlines Expected Upcoming Milestones
Moleculin Biotech Inc expected to post a loss of 27 cents a share - Earnings Preview
Brief: Moleculin Biotech Investigating Potential 'Naked Short Selling' Of Its Stock, And Has Retained Shareholder Intelligence Services
Brief: Moleculin Biotech Announces Adjournment Of 2023 Annual Meeting To June 15, 2023
Moleculin Biotech Inc reports results for the quarter ended in March - Earnings Summary